US-based Gilead Sciences` remdesivir, a potential antiviral drug to treat COVID-19 patients and is under several trials around the world, has reportedly failed to produce desired results during a Chinese trial study, the Financial Times reported on Thursday.
from Zee News :World https://ift.tt/2xTI1Gv
from Zee News :World https://ift.tt/2xTI1Gv